Advertisement
BDX vs COO
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. The Cooper Companies (COO) Stock Comparison
Key Takeaways
- BDX (Becton, Dickinson and Company) has transitioned into a focused medical technology company after a major business separation, and recently reported results that exceeded expectations while raising its full-year earnings outlook.
- COO (The Cooper Companies) has faced leadership turnover, channel-inventory destocking, and a cut to its near-term outlook, pressuring its share price in recent weeks.
- Tickeron AI Verdict: The relative momentum, trend consistency, and catalyst profile currently favor BDX over COO in this comparison.
- The two companies operate in different healthcare niches — medical technology and consumables versus vision care and women's health — producing contrasting growth and risk profiles.
- For more on each company's latest developments, explore BDX Major News, BDX Today's Price Move, COO Major News, and COO Today's Price Move.
- To see which automated strategies are currently favored across the market, explore Trending AI Robots.
Introduction
Investors comparing BDX and COO are weighing two large-cap healthcare names with very different operating models. Becton, Dickinson and Company is a diversified medical technology and consumables manufacturer, while The Cooper Companies spans contact lenses (CooperVision) and women's health and fertility (CooperSurgical). This comparison is relevant to traders assessing relative performance and market positioning, as well as longer-term investors evaluating growth durability, capital returns, and execution risk across the healthcare sector. Recent developments — a portfolio separation at BDX and leadership change with inventory adjustments at COO — have widened the divergence in how each stock is currently behaving.
BDX Overview and Recent Performance
Becton, Dickinson and Company (BDX), widely known as BD, operates as a focused medical technology company across segments including medical essentials, connected care, biopharma systems, and interventional products. In recent months the company completed the separation of its former Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation, reshaping BD into a pure-play MedTech operation under its "New BD" strategy.
Recent market activity has been constructive for BDX. The company reported quarterly revenue ahead of expectations, driven by double-digit growth in platforms such as biologic drug delivery, advanced patient monitoring, and PureWick, and it raised the midpoint of its full-year adjusted earnings-per-share (EPS) guidance to a range of roughly $12.52 to $12.72. A landmark agreement to invest approximately $19 billion in U.S. manufacturing over several years has reinforced its supply-chain positioning, while a $2 billion accelerated share repurchase and an ongoing dividend underscore shareholder returns. Over a six-month span, the stock has gained more than 20%, reflecting improving execution and earnings visibility.
COO Overview and Recent Performance
The Cooper Companies (COO) operates through CooperVision, a leading contact-lens business with premium brands such as MyDay, Biofinity, and MiSight, and CooperSurgical, which supplies fertility, women's health, and surgical products including the Paragard intrauterine device (IUD). The company does not currently pay a regular dividend.
Recent weeks have been more challenging for COO. Its latest quarterly revenue was roughly flat year over year, missing estimates as proactive U.S. channel-inventory reductions at CooperVision weighed on reported growth, even as underlying demand and premium products such as MiSight grew. Management lowered its near-term outlook, and the company announced that Chief Executive Albert White is stepping down, with an interim leader overseeing operations. The board also concluded a strategic review and elected to retain CooperSurgical while expanding its buyback authorization. The share price declined sharply following these announcements, with the stock down more than 20% year to date.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's artificial-intelligence-driven trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, yet only a select group earns a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance record, statistics, and universe of tickers, allowing users to match a bot to their preferred approach and risk tolerance. The Trending AI Robots list is designed to surface the bots best suited to current market conditions, providing a practical starting point for traders evaluating automated strategies. Explore Trending AI Robots to review the currently featured bots.
Head-to-Head Comparison
Business-model contrasts define much of this stock comparison. BDX is a large, diversified manufacturer with exposure to hospital consumables, drug delivery, pharmacy automation, and interventional devices, generating consistent free cash flow and returning capital through buybacks and a dividend. COO is more concentrated, with premium contact lenses and fertility services driving growth but also exposing it to channel dynamics and regional softness, particularly in Asia Pacific and China.
Growth drivers also differ. BDX is benefiting from biologics and GLP-1 (glucagon-like peptide-1) drug-delivery demand, advanced monitoring, and manufacturing reshoring. COO is leaning on premium daily lenses and myopia control, while working through inventory normalization. On market sentiment, BDX shows rising momentum and upgraded guidance, whereas COO faces leadership uncertainty and a reset outlook. Risk factors include tariffs and reimbursement pressures for BDX, and execution and inventory risk for COO.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings momentum, catalyst clarity, and relative positioning, Tickeron's AI would currently favor BDX over COO. BDX has demonstrated more stable upward momentum, delivered results ahead of expectations, raised guidance, and introduced concrete long-term catalysts, including its U.S. manufacturing investment and growing GLP-1 drug-delivery exposure. By contrast, COO is navigating leadership transition, guidance reductions, and inventory adjustments that have weighed on both its share price and sentiment. This assessment reflects a probabilistic reading of current conditions rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Buy and COO is a Hold.
BDX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BDX turned positive on October 09, 2026. Looking at past instances where BDX's MACD turned positive, the stock continued to rise in 26 of 45 cases over the following month. The odds of a continued upward trend are 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BDX as a result. In 54 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
BDX moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BDX crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +7.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDX advanced for three days, in 134 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 114 of 218 cases where BDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
BDX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. BDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.364) is normal, around the industry mean (4.964). P/E Ratio (63.819) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.107) is also within normal values, averaging (4.143). BDX has a moderately high Dividend Yield (0.020) as compared to the industry average of (0.005). P/S Ratio (2.290) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
COO in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 04, 2026
COO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 25 of the 38 cases the stock fell afterwards. This puts the odds of success at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for COO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 10 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 36%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 63 cases where COO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on COO as a result. In 45 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
COO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for COO crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where COO advanced for three days, in 152 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 115 of 222 cases where COO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. COO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.424) is normal, around the industry mean (4.964). P/E Ratio (21.283) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.532) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.526) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BDX | COO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 38 | 83 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 59 Fair valued | |
PROFIT vs RISK RATING 1..100 | 59 | 100 | |
SMR RATING 1..100 | 85 | 80 | |
PRICE GROWTH RATING 1..100 | 3 | 49 | |
P/E GROWTH RATING 1..100 | 5 | 85 | |
SEASONALITY SCORE 1..100 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COO's Valuation (59) in the Medical Specialties industry is in the same range as BDX (75). This means that COO’s stock grew similarly to BDX’s over the last 12 months.
BDX's Profit vs Risk Rating (59) in the Medical Specialties industry is somewhat better than the same rating for COO (100). This means that BDX’s stock grew somewhat faster than COO’s over the last 12 months.
COO's SMR Rating (80) in the Medical Specialties industry is in the same range as BDX (85). This means that COO’s stock grew similarly to BDX’s over the last 12 months.
BDX's Price Growth Rating (3) in the Medical Specialties industry is somewhat better than the same rating for COO (49). This means that BDX’s stock grew somewhat faster than COO’s over the last 12 months.
BDX's P/E Growth Rating (5) in the Medical Specialties industry is significantly better than the same rating for COO (85). This means that BDX’s stock grew significantly faster than COO’s over the last 12 months.
| BDX | COO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 63% | 1 day ago 36% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 54% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 51% |
| MACD ODDS (%) | 1 day ago 58% | N/A |
| TrendWeek ODDS (%) | 1 day ago 50% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 52% | 1 day ago 52% |
| Advances ODDS (%) | 6 days ago 46% | 22 days ago 56% |
| Declines ODDS (%) | 15 days ago 42% | 5 days ago 60% |
| BollingerBands ODDS (%) | 1 day ago 51% | 1 day ago 66% |
| Aroon ODDS (%) | 1 day ago 52% | 1 day ago 52% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 2 FA rating(s) are green while COO’s FA Score has 0 green FA rating(s).
- BDX’s FA Score: 2 green, 3 red.
- COO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 6 TA indicator(s) are bullish while COO’s TA Score has 5 bullish TA indicator(s).
- BDX’s TA Score: 6 bullish, 4 bearish.
- COO’s TA Score: 5 bullish, 4 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +8.38% price change this week, while COO (@Pharmaceuticals: Other) price change was +4.29% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.53%. For the same industry, the average monthly price growth was +4.73%, and the average quarterly price growth was +18.71%.
Reported Earning Dates
BDX is expected to report earnings on Feb 04, 2027.
COO is expected to report earnings on Dec 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+5.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with A. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To COO | 1D Price Change % | ||
|---|---|---|---|---|
| COO | 100% | +2.52% | ||
| A - COO | 50% Loosely correlated | +3.10% | ||
| BDX - COO | 50% Loosely correlated | +1.59% | ||
| ICUI - COO | 48% Loosely correlated | +3.92% | ||
| SOLV - COO | 47% Loosely correlated | +0.06% | ||
| DHR - COO | 46% Loosely correlated | +2.12% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| PIXEL.X | 0.004073 | 0.000213 | +5.51% |
| Pixels cryptocurrency | |||
| ONT.X | 0.040854 | 0.001266 | +3.20% |
| Ontology cryptocurrency | |||
| IMX.X | 0.119779 | 0.000641 | +0.54% |
| Immutable cryptocurrency | |||
| BTS.X | 0.000829 | -0.000014 | -1.61% |
| BitShares cryptocurrency | |||
| POLY.X | 0.000863 | -0.000042 | -4.64% |
| Polymath cryptocurrency | |||